case_images: PMC10837102_01
case_images: MRI brain wwo contrast. FLAIR (left) reveals periventricular white matter hyperintensities, and T1 with contrast (right) shows no contrast enhancement.. wwo: With and without; FLAIR: Fluid-attenuated inversion recovery.
case_images: cureus-0016-00000051614-i01.jpg
case_images: PMC10837102_01_cureus-0016-00000051614-i01.jpg
case_images: FIG1
case_images: MRI of cervical and thoracic spines, and positron emission tomography (PET) of the brain and body, which was obtained to rule out primary tumors, were all unremarkable. MRI of the brain and orbits with and without (wwo) contrast was obtained, which showed T2/fluid-attenuated inversion recovery (FLAIR) signal hyperintensity and homogeneous enhancement of the left retro-orbital optic tract proximally (Figures 1, 2).
case_images: MRI orbits wwo contrast. T2 FLAIR (left) reveals signal hyperintensity and T1 with contrast in the coronal section (right) shows homogeneous enhancement of the left retro-orbital optic tract.. wwo: With and without; FLAIR: Fluid-attenuated inversion recovery.
case_images: cureus-0016-00000051614-i02.jpg
case_images: PMC10837102_01_cureus-0016-00000051614-i02.jpg
case_images: FIG2
case_images: MRI of cervical and thoracic spines, and positron emission tomography (PET) of the brain and body, which was obtained to rule out primary tumors, were all unremarkable. MRI of the brain and orbits with and without (wwo) contrast was obtained, which showed T2/fluid-attenuated inversion recovery (FLAIR) signal hyperintensity and homogeneous enhancement of the left retro-orbital optic tract proximally (Figures 1, 2).
case_images: PMC10837102_02
case_images: (A-C) Hematoxylin and eosin stain. (D) Glial fibrillary acidic protein stain. (E) Isocitrate dehydrogenase (IDH1, R132H). (F) Ki-67.
case_images: cureus-0016-00000051614-i03.jpg
case_images: PMC10837102_02_cureus-0016-00000051614-i03.jpg
case_images: FIG3
case_images: Her left optic nerve was biopsied, which confirmed the diagnosis of optic pathway glioma (Figure 3).